Black Diamond Therapeutics
Black Diamond Therapeutics reported revenue of $70 million in fiscal 2025. Its operating margin was 17.9%. The diluted share count rose 4.6%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Black Diamond Therapeutics does
Black Diamond Therapeutics is a clinical-stage cancer drug developer. It has no approved products. It is working on what it calls MasterKey therapies, drugs meant to block whole families of cancer-driving gene mutations with one molecule, including in tumors in the brain.
Its lead program is silevertinib, an oral drug that targets a protein called EGFR. It is being tested in a Phase 2 clinical trial in patients with EGFR-mutant non-small cell lung cancer. The company plans to begin a randomized Phase 2 trial in newly diagnosed patients with an EGFR-altered brain cancer called glioblastoma in the second quarter of 2026.
The company has not generated any revenue from its product candidates. It found its drug candidates with its own discovery platform, and it has no sales or marketing organization. It competes with other companies developing cancer treatments.
Its biggest risks, as it describes them
- Trials failing to show that its drugs are safe and work, or being delayed by slow patient enrollment.
- Not winning the regulatory approvals it needs to sell a drug.
- No revenue from its product candidates, so it may never be profitable.
- Running its lead trial at sites outside the U.S., which U.S. regulators may not accept.
- Competition from others developing cancer drugs, and no sales team of its own.
Income statement
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 210 | 123 | 131 | 99 | 129 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 9.1x | 8.4x | 6.8x | 4.9x | 8.4x |
| Quick ratio | 9.1x | 8.4x | 6.8x | 4.9x | 8.4x |
Cash flow
Projections
Project Black Diamond Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Black Diamond Therapeutics says to expect
- Cash runway
The Company believes that its existing cash, cash equivalents and investments, will be sufficient to fund its anticipated operating expenses and capital expenditure requirements into the second half of 2028.
Insider trades
No officer, director or 10% owner of Black Diamond Therapeutics reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | — | — |
| Altman Z'' | −4.58 | −10.73 | −0.83 |
| Accruals ratio | −10.0% | −5.2% | −5.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Pass |
| Cash from operations is positive | Fail | Fail | Pass |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | — | Pass |
| F-score | — | — | — |
Compare
Put Black Diamond Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Black Diamond Therapeutics | FY25 | — | 17.9% | — | — | — | — | |
| Vir Biotechnology | FY25 | −7.6% | −699.2% | −578.5% | — | — | — | Compare |
| Intellia Therapeutics | FY25 | 16.9% | −651.7% | −585.0% | — | — | — | Compare |
| Bicycle Therapeutics | FY25 | 105.8% | −340.4% | −347.2% | — | — | — | Compare |
| Compugen | FY25 | 161.1% | 43.0% | 43.0% | — | — | — | Compare |
8 years of figures
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 0 | 0 | 0 | — | — | — | 0 | 70 |
| Revenue growth | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Research and development | 7 | 22 | 48 | 97 | 64 | 59 | 51 | 34 |
| Operating income | −9 | −29 | −70 | −127 | −93 | −86 | −79 | 12 |
| Net income | −9 | −35 | −67 | −126 | −91 | −82 | −70 | 22 |
| Diluted EPS (US$) | −4.42 | −16.99 | −2.05 | −3.47 | −2.52 | −1.88 | −1.27 | 0.39 |
| Diluted shares (millions) | 2 | 2 | 33 | 36 | 36 | 44 | 55 | 58 |
| Cash flow | ||||||||
| Cash from operations | −8 | −25 | −52 | −100 | −85 | −67 | −62 | 30 |
| Capital expenditure | 0 | 0 | 0 | 3 | 0 | 0 | 0 | — |
| Free cash flow | −9 | −25 | −52 | −103 | −85 | −67 | −62 | — |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 4 | 8 | 14 | 12 | 10 | 11 | 7 |
| Balance sheet at fiscal year end | ||||||||
| Cash and short-term investments | 52 | 155 | 315 | 210 | 123 | 131 | 99 | 129 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — |
| Total assets | 52 | 158 | 330 | 248 | 156 | 159 | 123 | 143 |
| Total liabilities | 7 | 5 | 22 | 52 | 41 | 42 | 39 | 31 |
| Shareholders' equity | −16 | −47 | 308 | 196 | 116 | 117 | 83 | 112 |
| Margins and ratios | ||||||||
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | 17.9% |
| Net margin | — | — | — | — | — | — | — | 31.9% |
| Free cash flow margin | — | — | — | — | — | — | — | — |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | — | — |
| Return on capital | — | — | — | — | — | — | — | — |
| Return on equity | — | — | −51.6% | −49.9% | −58.5% | −70.9% | −69.7% | 22.9% |
| Return on assets | — | −33.6% | −27.6% | −43.5% | −45.1% | −52.4% | −49.5% | 16.8% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — |